20 Takeover Rumors Hedge Funds Are Buying

Page 5 of 18

14. Arcellx, Inc. (NASDAQ:ACLX)

No. of Hedge Funds: 37

A clinical-stage biotechnology company, Arcellx, Inc. (NASDAQ:ACLX) deals with advancing novel cell therapy platforms for treating cancer and autoimmune diseases. The company’s proprietary D-Domain technology underpins ARC-SparX, a modular CAR-T cell platform with high safety and precision. Located in California, the company primarily competes with other oncology-focused biotech firms but shines above them through its flexible dosing architecture and potential for off-the-shelf applications that target the unmet medical needs in hematologic malignancies.

Arcellx, Inc. (NASDAQ:ACLX) holds strong data from its Phase II iMMagine-1 trial for treating relapsed or refractory multiple myeloma patients, making the company a notable target for takeover. The takeover rumors surrounding the company extend beyond the potential takeover by Gilead Sciences, a partner in developing anito-cel for multiple myeloma, with some analysts in 2024 believing a bid from another company could top this combination. The company’s introduction of cell therapy has shown efficiency in treating EMD, a condition where other CAR-T therapies have performed poorly. It increases the takeover speculations with other companies, as such would provide the company with greater financial and commercial benefits.

The company has attracted investments from 37 hedge funds, suggesting a moderate level of institutional engagement. Arcellx, Inc. (NASDAQ:ACLX)’s strong intrinsic worth, backed by institutional interest, could have emerged from recent acquisition speculation.

Page 5 of 18